Marginal zone lymphomas (MZL) represent a group of indolent B-cell lymphomas that arises from
marginal zone B-cells in extranodal tissues, such as spleen and mucosa associated lymphoid
tissues, and more rarely also in nodal tissues. MZL comprises 5 to 17% of all non-Hodgkin
lymphomas (NHL) in adults. The 2016 World Health Organization (WHO) recognized three separate
subtypes of MZL according to their primary localization, namely the:
1. extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT), also known as MALT
2. splenic MZL (SMZL)
3. nodal MZL (NMZL). These three subtypes are distinct disease entities that are classified
together because they all seem to originate from post germinal centre marginal zone
MALIBU trial is a prospective multicenter trial combining rituximab and ibrutinib in
front-line for patients with MZL, including EMZL, SMZL and NMZL Aim of the study is to assess
the safety and efficacy of the combination of rituximab and ibrutinib in EMZL patients and to
explore its activity in SMZL and NMZL as exploratory subset.
Chemotherapy and immunotherapy-naïve, symptomatic and in need of treatment patients, with
histologically proven CD20-positive MZL, not eligible for local therapy, including:
1. EMZL (MALT Lymphoma) patients with MALT- IPI score 1-2 in need of systemic therapy.
Either de novo or relapsed following local therapy (including surgery, radiotherapy
and antibiotics for H. pylori-positive gastric lymphoma) arisen at any extranodal site
with MALT-international prognostic index (IPI) score 1-2 at the time of study entry.
1.1.The following patients with gastric MALT Lymphoma can be entered:
1. H. pylori-negative cases, either de novo (non pretreated) or at relapse following
local therapy (i.e., surgery, radiotherapy or antibiotics).
2. H. pylori-positive cases at diagnosis, who either first line antibiotics or
further local treatment (surgery or radiotherapy), including patients with:
- clinical (endoscopic) and histological evidence of disease progression at
any time post H. pylori eradication;
- clinical (endoscopic) and histological relapse (without H. pylori
re-infection), after a remission patients;
- persistent (stable) lymphoma at ≥ 1 year post H. pylori eradication.
1.2. Similar consideration may be applied to patients with ocular
adnexal lymphoma treated with antibiotics.
2. SMZL patients in need of therapy. Either de novo or relapsed following local therapy
[including surgery and antiviral therapy for Hepatitis C virus (HCV)]. Patient must
have a symptomatic disease requiring treatment and be not eligible for splenectomy or
not willing to undergo splenectomy.
2.1. Patients with SMZL can be entered if any of the following criteria is present:
1. bulky progressive or painful splenomegaly;
2. enlarged lymph nodes or involvement of extranodal sites with or without
3. one of the following symptomatic/progressive cytopenias:
- Hgb < 10 g/dL;
- ANC < 1000/μL:
- PLT< 80 000/μL whatever the reason (autoimmune or hypersplenism or bone
2.2. Splenectomised patients with rapidly raising lymphocyte counts, lymphadenopathy
or involvement of extranodal sites can be entered.
2.3. SMZL with concomitant HCV infection who have not responded to or are relapsed
after antiviral therapy can be entered.
3. NMZL patients in need of therapy Either, de novo presenting with disseminated disease
or relapsed after local radiotherapy or following antiviral therapy for HCV. Localized
nodal MZL is not eligible.
- Measurable or evaluable disease.
- Ann Arbor II-IV. Stage I disease may be eligible only if not candidate to local
therapy (surgery or radiotherapy).
- Age ≥ 18.
- Life expectancy of at least 1 year.
- ECOG Performance status 0-2.
- Adequate bone marrow, kidney and liver function
- For women of childbearing potential only: negative serum pregnancy test done
within 7 days prior to study drugs administration or within 14 days if with a
confirmatory urine pregnancy test within 7 days prior to the first study drugs
- Fertile male or female patients of childbearing potential and their partners must
use two forms of contraception during the study and for at least 12 months after
the last dose of subcutaneous rituximab.
- Ability to understand and the willingness to sign a written informed consent
1. Any type of lymphoma other than MZL (including MZL with histologic transformation to
2. Localized (stage IE and IIE) gastric, ocular and cutaneous MALT lymphoma that may
benefit from local therapy only (surgery or radiotherapy).
3. Known CNS involvement of MZL.
4. Any previous systemic treatment with immunotherapy or chemotherapy or with BTK
5. Major surgery within 4 weeks prior to registration.
6. History of stroke or intracranial bleeding within 6 months.
7. Known bleeding diathesis (eg, von Willebrand's disease) or hemophilia.
8. Concurrent use of warfarin of other vitamin K antagonists.
9. Concurrent use of strong cytochrome P450 (CYP)3A4/5 inhibitors (see
10. Any life-threatening illness, medical condition, or organ system dysfunction which, in
the investigator's opinion, could compromise the subject's safety, interfere with the
absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue
11. Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization.
12. Clinically significant hypersensitivity (e.g., anaphylactic or anaphylactoid reactions
to the compound of ibrutinib itself or to the excipients in its formulation).
13. Active HCV or Hepatitis B virus (HBV) infections.
14. HIV infection or immunodeficiency.
15. Pregnancy or breastfeeding.
16. Clinically significant cardiovascular diseases such as uncontrolled or symptomatic
arrhythmias, congestive heart failure, or myocardial infarction within 6 months of
screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by
the New York Heart Association Functional Classification.
17. Any serious medical or psychiatric illness likely to interfere with participation in
this clinical study.
18. Prior history of malignancies other than MZL within 3 years